Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients

Trial Profile

Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Olaparib (Primary) ; Carboplatin; Paclitaxel
  • Indications Ovarian cancer; Uterine cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Apr 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
    • 25 Apr 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
    • 20 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top